Free Trial
NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis

Bellerophon Therapeutics logo
$0.06 +0.02 (+57.14%)
(As of 11/21/2024 ET)

About Bellerophon Therapeutics Stock (NASDAQ:BLPH)

Key Stats

Today's Range
$0.04
$0.06
50-Day Range
$0.04
$0.06
52-Week Range
$0.03
$0.10
Volume
276 shs
Average Volume
31,595 shs
Market Capitalization
$672,650.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Bellerophon Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
9th Percentile Overall Score

BLPH MarketRank™: 

Bellerophon Therapeutics scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Bellerophon Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bellerophon Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bellerophon Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bellerophon Therapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for BLPH.
  • Dividend Yield

    Bellerophon Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bellerophon Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BLPH.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Bellerophon Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for BLPH on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bellerophon Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Bellerophon Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 10.61% of the stock of Bellerophon Therapeutics is held by institutions.

  • Read more about Bellerophon Therapeutics' insider trading history.
Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BLPH Stock News Headlines

Central Bank Abandons USD
You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD!
Bellerophon Therapeutics, Inc. (BLPH)
Bellerophon Therapeutics Inc (BLPH)
See More Headlines

BLPH Stock Analysis - Frequently Asked Questions

Bellerophon Therapeutics' stock was trading at $0.0370 at the beginning of the year. Since then, BLPH shares have increased by 48.6% and is now trading at $0.0550.
View the best growth stocks for 2024 here
.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter.

Bellerophon Therapeutics shares reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Bellerophon Therapeutics (BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), iBio (IBIO) and Meta Platforms (META).

Company Calendar

Last Earnings
8/14/2023
Today
11/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BLPH
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.27 per share

Miscellaneous

Free Float
11,597,000
Market Cap
$672,650.00
Optionable
No Data
Beta
0.71

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:BLPH) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners